A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors
Open Access
- 13 January 2006
- journal article
- research article
- Published by Elsevier BV in Journal of Thrombosis and Haemostasis
- Vol. 4 (2), 367-371
- https://doi.org/10.1111/j.1538-7836.2006.01772.x
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society RegistryHaemophilia, 2005
- Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activityJournal of Thrombosis and Haemostasis, 2004
- Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitorsJournal of Thrombosis and Haemostasis, 2004
- How factor VIIa works in hemophiliaJournal of Thrombosis and Haemostasis, 2003
- Massive pseudotumour resection with recombinant factor VIIa (NovoSeven) coverBritish Journal of Haematology, 2002
- Mechanism of factor VIIa–dependent coagulation in hemophilia bloodBlood, 2002
- Rationale for the use of high dose rFVIIa in a high-titre inhibitor patient with haemophilia B during major orthopaedic proceduresHaemophilia, 2001
- Inhibition of thrombin generation by the zymogen factor VII: implications for the treatment of hemophilia A by factor VIIaBlood, 2000
- Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: the advantages of early interventionBritish Journal of Haematology, 1999
- Home Treatment of Mild to Moderate Bleeding Episodes Using Recombinant Factor VIIa (Novoseven) in Haemophiliacs with InhibitorsThrombosis and Haemostasis, 1998